A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

被引：0
|
作者：
A H Ko
M A Tempero
Y-S Shan
W-C Su
Y-L Lin
E Dito
A Ong
Y-W Wang
C G Yeh
L-T Chen
机构：
[1] Comprehensive Cancer Center,Division of Hematology/Oncology
[2] University of California,Department of Surgery
[3] San Francisco,Department of Internal Medicine
[4] National Cheng Kung University Hospital,Department of Oncology
[5] National Cheng Kung University Hospital,Department of Internal Medicine and Cancer Center
[6] National Taiwan University Hospital,undefined
[7] PharmaEngine,undefined
[8] Inc.,undefined
[9] National Institute of Cancer Research,undefined
[10] National Health Research Institutes,undefined
[11] Kaohsiung Medical University Hospital,undefined
[12] Kaohsiung Medical University,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
Irinotecan sucrosofate; liposome; pancreatic cancer; second-line; gemcitabine-refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：920 / 925
页数：5
相关论文
共 50 条
  • [1] A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
    Ko, A. H.
    Tempero, M. A.
    Shan, Y-S
    Su, W-C
    Lin, Y-L
    Dito, E.
    Ong, A.
    Wang, Y-W
    Yeh, C. G.
    Chen, L-T
    BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 920 - 925
  • [2] A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer
    Ko, A. H.
    Tempero, M. A.
    Shan, Y.
    Su, W.
    Lin, Y.
    Dito, E.
    Ong, A.
    Yeh, G.
    Chen, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer
    Ko, A. H.
    Tempero, M. A.
    Shan, Y.
    Su, W.
    Lin, Y.
    Dito, E.
    Ong, A.
    Wang, Y.
    Yeh, G.
    Chen, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer
    Chiang, Nai-Jung
    Chang, Jang-Yang
    Shan, Yan-Shen
    Chen, Li-Tzong
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (10) : 1413 - 1420
  • [5] PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
    Chibaudel, Benoist
    Maindrault-Goebel, Frederique
    Bachet, Jean-Baptiste
    Louvet, Christophe
    Khalil, Ahmed
    Dupuis, Olivier
    Hammel, Pascal
    Garcia, Marie-Line
    Bennamoun, Mostefa
    Brusquant, David
    Tournigand, Christophe
    Andre, Thierry
    Arbaud, Claire
    Larsen, Annette K.
    Wang, Yi-Wen
    Yeh, C. Grace
    Bonnetain, Franck
    de Gramont, Aimery
    CANCER MEDICINE, 2016, 5 (04): : 676 - 683
  • [6] Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
    Chen, L-T.
    Li, C-P.
    Chiu, C-F.
    Shan, Y-S.
    Park, J. O.
    Chen, J-S.
    Kim, J. S.
    Rau, K-M.
    de Jong, F.
    Pipas, M.
    Belanger, B.
    Wang, E.
    Lee, K-H.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy.
    Chen, Li-Tzong
    Shiah, Her-Shyong
    Lin, Peng-Chan
    Lee, Jenq-Chang
    Su, Wu-Chou
    Wang, Yi-Wen
    Yeh, Grace
    Chang, Jang-Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [8] Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
    Chang, T. C.
    Shiah, H. S.
    Yang, C. H.
    Yeh, K. H.
    Cheng, A. L.
    Shen, B. N.
    Wang, Y. W.
    Yeh, C. G.
    Chiang, N. J.
    Chang, J. Y.
    Chen, L. T.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 579 - 586
  • [9] Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
    T. C. Chang
    H. S. Shiah
    C. H. Yang
    K. H. Yeh
    A. L. Cheng
    B. N. Shen
    Y. W. Wang
    C. G. Yeh
    N. J. Chiang
    J. Y. Chang
    L. T. Chen
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 579 - 586
  • [10] MM-398 Achieves Primary Endpoint of Overall Survival in Phase III Study in Patients with Gemcitabine Refractory Metastatic Pancreatic Cancer
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2014, 15 (03): : 278 - 279
12345